Privium Fund Management B.V. Avidity Biosciences, Inc. Transaction History
Privium Fund Management B.V.
- $354 Million
- Q2 2024
A detailed history of Privium Fund Management B.V. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Privium Fund Management B.V. holds 22,242 shares of RNA stock, worth $937,945. This represents 0.26% of its overall portfolio holdings.
Number of Shares
22,242
Previous 8,042
176.57%
Holding current value
$937,945
Previous $205,000
342.93%
% of portfolio
0.26%
Previous 0.06%
Shares
2 transactions
Others Institutions Holding RNA
# of Institutions
206Shares Held
95.5MCall Options Held
171KPut Options Held
196K-
Price T Rowe Associates Inc Baltimore, MD10.9MShares$460 Million0.05% of portfolio
-
Rtw Investments, LP New York, NY8.81MShares$371 Million6.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$364 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.51MShares$274 Million3.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.94MShares$251 Million0.0% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $2.2B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...